Co-expression of CCR4 improved the homing ability of anti-CD30 CAR-T cells to Hodgkin tumor sites by enhancing their migration toward CCR4 ligands CCL17 and CCL22, which are highly expressed in the tumor microenvironment (182). This evidence concerns the gene TNFRSF8 and neoplasm.